# FACIT

> FACIT is a VC fund in Toronto backing Biotechnology, Health Care and Medical Device. See 31 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Toronto, Canada
- Total investments: 31
- Last investment: Jan 2025
- Lead investor: 26%
- Last updated: Aug 2026
- Website: https://facit.ca/

FACIT is a commercialization venture firm that builds companies with entrepreneurs to accelerate oncology innovation, with a portfolio that has attracted over $850 million in investment to Ontario. Blending industry experience, capital and the unsurpassed clinician-scientist network of its strategic partner the Ontario Institute for Cancer Research(OICR), FACIT capitalizes on the province's investment in research and healthcare to the benefit of the local economy and patients worldwide.

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $1.5M–$8M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 13 | 42% |
| Health Care | 8 | 26% |
| Medical Device | 6 | 19% |
| Medical | 5 | 16% |
| Life Science | 5 | 16% |

26 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 15 | 48% |
| Funding Round | 4 | 13% |
| Pre-Seed | 2 | 6% |
| Series A | 2 | 6% |
| Series B | 2 | 6% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Canada | 21 | 68% |
| United States | 3 | 10% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Esphera SynBio | Esphera SynBio operates as a biotechnology company. Esphera SynBio provides practitioners of synthetic biology for the treatment and prevention of disease. | $2M | Seed | Jan 07, 2025 |  |
| Hyivy Health | Hyivy Health creates an intelligent and holistic pelvic rehabilitation device for the 1 in 3 women worldwide who will experience a pelvic health complication in their lifetime. Our device provides the first quantifiable data set on the pelvic floor and 3 different therapies from multiple sensors and mechanical functions to help keep track ofprogress, adapt treatment plans and provide more effective, comfortable rehab experiences. | $1.5M | Seed | Sep 24, 2024 |  |
| Radiant Biotherapeutics | Radiant Biotherapeutics is a revolutionary antibody platform company leading the new frontier of multi-valent, multi-specific therapeutics to deliver transformative therapies for patients. | $35M | Series A | Sep 11, 2024 |  |
| HDAX Therapeutics | HDAX Therapeutics is pioneering next-gen precision therapeutics for cardiovascular and neurological diseases by targeting their root causes to enhance patient outcomes. | $3.2M | Seed | Sep 05, 2024 |  |
| HDAX Therapeutics | HDAX Therapeutics is pioneering next-gen precision therapeutics for cardiovascular and neurological diseases by targeting their root causes to enhance patient outcomes. | $3.2M | Seed | Sep 05, 2024 |  |
| Tenomix | Tenomix mission is to develop novel technologies that target inefficiencies in the pathology workflow optimize cancer care and reduce healthcare costs | $1.6M | Seed | Mar 01, 2024 |  |
| Radiant Biotherapeutics | Radiant Biotherapeutics is a revolutionary antibody platform company leading the new frontier of multi-valent, multi-specific therapeutics to deliver transformative therapies for patients. | $8M | Seed | Apr 25, 2023 |  |
| CTRL Therapeutics | CTRL Therapeutics operates a biotechnology company that researches on cell therapy development and treatment. It is based in Toronto, Canada. | $10M | Seed | Apr 10, 2023 |  |
| HDAX Therapeutics | HDAX Therapeutics is pioneering next-gen precision therapeutics for cardiovascular and neurological diseases by targeting their root causes to enhance patient outcomes. |  | Seed | Sep 28, 2022 |  |
| QurCan Therapeutics Inc. | Nanology Labs has designed and is developing Manganescan®, a novel theranostic agent (MRI contrast agent/Radio-sensitizer) that allows detection of brain tumors at early stages using MRI. Simultaneously, it sensitizes cancer cells which improves radiation therapy outcomes. The agent is 3x more sensitive than current Gadolinium contrast agents(GBCAs), can cross the blood brain barrier and enables early and precise detection and targeting of brain cancer. | $3M | Seed | May 17, 2021 |  |

10 of 31 investments shown.

## Co-investors
- [Toronto Innovation Acceleration Partners](https://shizune.co/investors/profile/mars-innovation-mi) — VC Fund, 4 deals together
- [Ontario Centre of Innovation](https://shizune.co/investors/profile/oci-e51e) — VC Fund, 4 deals together
- [Ontario Bioscience Industry Organization](https://shizune.co/investors/profile/ontario-bioscience-industry-organization) — VC Fund, 3 deals together
- [Amplitude Venture Capital](https://shizune.co/investors/profile/amplitude-venture-capital) — VC Fund, 2 deals together
- [Anges Quebec](https://shizune.co/investors/profile/anges-quebec) — VC Fund, 2 deals together
- [Creative Destruction Lab](https://shizune.co/investors/profile/creative-destruction-lab) — VC Fund, 2 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [BDC Venture Capital](https://shizune.co/investors/profile/bdc-venture-capital) — VC Fund
- [Real Ventures](https://shizune.co/investors/profile/real-ventures) — VC Fund
- [Anges Quebec](https://shizune.co/investors/profile/anges-quebec) — VC Fund

## Featured in investor lists
- [Health Care Investors in Canada](https://shizune.co/investors/health-care-investors-canada)
- [Health Care VC Funds in Canada](https://shizune.co/investors/health-care-vc-funds-canada)
- [Biotech Investors in Canada](https://shizune.co/investors/biotech-investors-canada)
- [Biotech VC Funds in Canada](https://shizune.co/investors/biotech-vc-funds-canada)
- [Biotechnology Investors in Canada](https://shizune.co/investors/biotechnology-investors-canada)
- [Life Science Investors in Canada](https://shizune.co/investors/life-science-investors-canada)

## FAQ

### What does FACIT invest in?

FACIT invests primarily in Biotechnology, Health Care and Medical Device startups, most often at Seed and Funding Round stage. Most of the 31 investments tracked by Shizune back companies in Canada. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is FACIT's check size?

FACIT typically joins rounds of $1.5M–$8M at Seed. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds FACIT participates in.

### When did FACIT last invest?

The most recent investment recorded for FACIT closed in Jan 2025. Shizune tracks 31 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co